Trial Profile
A retrospective study investigating discontinuation rates and reasons for discontinuation of delayed-release dimethyl fumarate in patients with multiple sclerosis analysed in Biogen ONE support program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2016
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 18 Nov 2016 New trial record